Strategic Intelligence Report
Generated July 30, 2026
AI Labs
Recursion Pharmaceuticals
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
0
Chokepoint Score
no direct dependencies recorded in the graph
Steady
Momentum
insider filing activity unchanged since last check
Headquarters
Salt Lake City, Utah, USA
Website
Founded
2013
Listing
RXRX · NASDAQ
Market Cap
$1.62B
Revenue (TTM)
$66.41M
Price
USD3.05 (-0.97%)
Market data as of Jul 29, 2026, 11:25 AM · Source: Yahoo Finance (delayed). Not investment advice.
Overview
A publicly traded 'TechBio' company applying AI foundation models and high-throughput automated labs to drug discovery, which showcased its collaboration with NVIDIA and HighRes Biosolutions on self-driving drug discovery labs at NVIDIA's GTC conference in February 2026. NVIDIA invested $50 million in Recursion in 2023 as part of a strategic collaboration to build BioHive-1-trained AI foundation models for biology and chemistry, though NVIDIA fully exited its equity position in a February 2026 13F filing while the operational partnership continued.
Dependency Map
One hop in each direction — see Strategic Connections below for the full, sourced breakdown of every relationship.
Strategic Connections
Dependency
- NVIDIA: Recursion's BioHive-1 supercomputer and AI foundation models for biology/chemistry were built with NVIDIA, including a $50 million NVIDIA investment in 2023; the companies showcased self-driving drug discovery labs together at NVIDIA's GTC 2026 conference even after NVIDIA exited its equity stake in February 2026.
Competition / Other
- Healthcare & Life Sciences: Recursion Pharmaceuticals applies AI and automated high-throughput labs to drug discovery within the healthcare and life sciences industry.
- Isomorphic Labs: Recursion competes with Isomorphic Labs and other AI-first drug discovery companies for pharma partnerships and computational drug-design leadership.
- Xaira Therapeutics: Recursion competes with Xaira Therapeutics and other AI drug discovery companies for pharma partnerships and top computational biology talent.
Strategic Risks
- NVIDIA's full exit from its equity stake, even amid a continuing operational partnership, raises questions about the durability of strategic-investor backing
- AI-driven drug discovery remains pre-commercial with no guarantee of translating computational leads into approved therapeutics
Future Outlook
- Continued high-throughput 'self-driving lab' automation expected to be a key differentiator versus computation-only rivals
- Pipeline progress toward clinical validation remains the central catalyst for the stock and business model
- Multiple near-term pipeline readouts expected in 2026 following the first AI-enabled FAP clinical proof of concept
Sources
- U.S. Securities and Exchange Commission (EDGAR) (Feb 2026) — Recursion Pharmaceuticals, Inc. FY2025 Annual Report (Form 10-K), filed with the SEC
- StocksToTrade (Feb 2026) — Recursion showcases AI-driven drug discovery with NVIDIA at GTC 2026
- CMC Markets (Feb 2026) — NVIDIA exits Recursion equity stake in February 2026 13F filing despite ongoing partnership
- SEC Form DEF 14A / company disclosures (Jun 2026) — Recursion cites 'inflection point' with first AI-enabled clinical proof of concept in FAP and fifth Sanofi milestone
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Full Analyst Report — switch to the Executive Summary.